Acetylation genotype and the genetic susceptibility to prostate cancer in a Southern European population

Prostate

Volumn 64, Issue 3, 2005, Pages 246-252

  Costa, Sandra ^a,b,d   Pinto, Daniela ^b   Morais, Antonio ^b   Vasconcelos, André ^b   Oliveira, Jorge ^b   Lopes, Carlos ^b,c   Medeiros, Rui ^b,c  

^a UNIVERSITY OF MINHO   (Portugal)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF MINHO   (Portugal)

Author keywords

Acetylation; Heterocyclic aromatic amines; NAT; Polymorphisms; Prostate cancer

Indexed keywords

ACYLTRANSFERASE; CARCINOGEN; CIGARETTE SMOKE;

ACETYLATION; ADULT; AGED; ARTICLE; CANCER RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; GENE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAT; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAT1 GENE; NAT2 GENE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SOUTHERN EUROPE; STATISTICAL SIGNIFICANCE;

ACETYLATION; AGED; ARYLAMINE N-ACETYLTRANSFERASE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ISOENZYMES; MALE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PORTUGAL; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 22144462833     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20241     Document Type: Article

References (35)

1. Pinheiro PS, Tycznski JE, Bray F, Amado J, Matos E, Parkin DM. Cancer incidence and mortality in Portugal. Eur J Cancer 2003; 39:2507-2520.
2. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861-2869.
3. Rodriguez C, Tatham LM, Thun MJ, Calle EE, Heath CW Jr. Smoking and fatal prostate cancer in a large cohort of adult men. Am J Epidemiol 1997;145:466-475.
4. Kolonel LN. Fat, meat, and prostate cancer. Epidemiol Rev 2001;23:72-81.
5. Wang CY, Debiec-Rychter M, Schut HA, Morse P, Jones RF, Archer C, King CM, Haas GP. N-acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium. Carcinogenesis 1999;20:1591-1595.
6. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993;14:1633-1638.
7. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: Isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990; 9:193-203.
8. Butcher NJ, Boukouvala S, Sim E, Minchin RF. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2002; 2:30-42.
9. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell'Omo M, Dolzan V, Dresler CM, Fryer A, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, van Lieshout EM, London S, Manni JJ, Maugard CM, Morita S, Nazar-Stewart V, Noda K, Oda Y, Pari FF, Pastorelli R, Persson I, Peters WH, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnet D, Strange RC, Stucker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Taioli E. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001;10:1239-1248.
10. Hein DW, Leff MA, Ishibe N, Sinha R, Frazier HA, Doll MA, Xiao GH, Weinrich MC, Caporaso NE. Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1*10) in combination with slow N-acetyltransferase 2 acetylator genotypes in a pilot case-control study. Environ Mol Mutagen 2002;40:161-167.
11. Hou SM, Ryberg D, Fait S, Deverill A, Tefre T, Borresen AL, Haugen A, Lambert B. GSTM1 and NAT2 polymorphisms in operable and non-operable lung cancer patients. Carcinogenesis 2000;21:49-54.
12. van der Hel OL, Peeters PH, Hein DW, Doll MA, Grobbee DE, Kromhout D, Bueno de Mesquita HB. NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics 2003;13:399-407.
13. Costa S, Medeiros R, Vasconcelos A, Pinto D, Lopes C. A slow acetylator genotype associated with an increased risk of advanced cervical cancer. J Cancer Res Clin Oncol 2002;128: 678-682.
14. Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, Gelatti U, Spaliviero M, Placidi D, Carta A, Scotto dC, Porru S. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer 2004;110: 598-604.
15. Brockton N, Little J, Sharp L, Cotton SC. N-acetyltransferase polymorphisms and colorectal cancer: A HuGE review. Am J Epidemiol 2000;151:846-861.
16. Payton MA, Sim E. Genotyping human arylamine N-acetyltransferase type 1 (NAT1): The identification of two novel allelic variants. Biochem Pharmacol 1998;55:361-366.
17. Lawson T, Kolar C. Human prostate epithelial cells metabolize chemicals of dietary origin to mutagens. Cancer Lett 2002;175: 141-146.
18. Mullenbach R, Lagoda PJ, Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet 1989; 5:391.
19. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) poly-adenylation signal: Association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995;55:5226-5229.
20. Gonzalez MV, Alvarez V, Pello MF, Menendez MJ, Suarez C, Goto E. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol 1998;51:294-298.
21. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993;118:793-803.
22. Ross RK, Henderson BE. Do diet and androgens alter prostate cancer risk via a common etiologic pathway? J Natl Cancer Inst 1994;86:252-254.
23. King CM, Land SJ, Jones RF, Debiec-Rychter M, Lee MS, Wang CY. Role of acetyltransferases in the metabolism and carcinogenicity of aromatic amines. Mutat Res 1997;376:123-128.
24. Xu J, Zheng SL, Hawkins GA, Faith DA, Kelly B, Isaacs SD, Wiley KE, Chang B, Ewing CM, Bujnovszky P, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB. Linkage and association studies of prostate cancer susceptibility: Evidence for linkage at 8p22-23. Am J Hum Genet 2001;69: 341-350.
25. Wadelius M, Autrup JL, Stubbins MJ, Andersson SO, Johansson JE, Wadelius C, Wolf CR, Autrup H, Rane A. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics 1999;9:333-340.
26. Hamasaki T, Inatomi H, Katoh T, Aono H, Ikuyama T, Muratani T, Matsumoto T. N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men. Int J Urol 2003;10:167-173.
27. Fukutome K, Watanabe M, Shiraishi T, Murata M, Uemura H, Kubota Y, Kawamura J, Ito H, Yatani R. N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development. Cancer Lett 1999;136:83-87.
28. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity. Am J Hum Genet 1995;57: 581-592.
29. Hein DW, Rustan TD, Ferguson RJ, Doll MA, Gray K. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch Toxicol 1994;68:129-133.
30. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Lopes C. The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. J Hum Genet 2002;47:413-418.
31. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Lopes C. Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev 2002;11:343-350.
32. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Carvalho R, Lopes C. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate 2002;53:88-94.
33. Ferreira PM, Medeiros R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J, Lopes C. Association between CYP2E1 polymorphisms and susceptibility to prostate cancer. Eur J Cancer Prev 2003;12:205-211.
34. Medeiros R, Vasconcelos A, Costa S, Pinto D, Ferreira P, Lobo F, Morais A, Oliveira J, Lopes C. Metabolic susceptibility genes and prostate cancer risk in a southern European population: The role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate 2004;58:414-420.
35. Ribeiro R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J, Lobo F, Lopes C, Medeiros R. Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 2004; 59:268-274.